#STOCK DGX PLUS#
#STOCK DGX FREE#

Forbes Media, LLC Investor's Business Daily, Inc. Each of the company logos represented herein are trademarks of Microsoft Corporation Dow Jones & Company Nasdaq, Inc. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Greenbrook TMS Inc.'s revenues are expected to be $19.15 million, up 34.8% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This company is expected to post quarterly loss of $0.29 per share in its upcoming report, which represents a year-over-year change of +29.3%.

#STOCK DGX FREE#

( GBNH Quick Quote GBNH - Free Report), has yet to report results for the quarter ended June 2023. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.Īnother stock from the same industry, Greenbrook TMS Inc.

#STOCK DGX PLUS#

In terms of the Zacks Industry Rank, Medical - Outpatient and Home Healthcare is currently in the top 49% of the 250 plus Zacks industries. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. The current consensus EPS estimate is $2.23 on $2.23 billion in revenues for the coming quarter and $8.67 on $9.02 billion in revenues for the current fiscal year. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. So, the shares are expected to underperform the market in the near future. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Īhead of this earnings release, the estimate revisions trend for Quest Diagnostics: unfavorable. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. While Quest Diagnostics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? Quest Diagnostics shares have lost about 7.4% since the beginning of the year versus the S&P 500's gain of 19%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. The company has topped consensus revenue estimates four times over the last four quarters. This compares to year-ago revenues of $2.45 billion. Quest Diagnostics, which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, posted revenues of $2.34 billion for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 4.22%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. A quarter ago, it was expected that this medical laboratory operator would post earnings of $1.97 per share when it actually produced earnings of $2.04, delivering a surprise of 3.55%. This quarterly report represents an earnings surprise of 3.14%. These figures are adjusted for non-recurring items.

This compares to earnings of $2.36 per share a year ago. Quest Diagnostics ( DGX Quick Quote DGX - Free Report) came out with quarterly earnings of $2.30 per share, beating the Zacks Consensus Estimate of $2.23 per share.

Stock dgx